Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours

MT Newswires Live12-10

Biomea Fusion (BMEA) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a "transformative" therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer.

The investigational therapy demonstrated a "favorable" safety and tolerability profile in the trial, with no dose-limiting toxicities observed across all dose levels, the company said.

"Given the safety profile demonstrated to date, and the lack of myelosuppression, we think BMF-500 could be an excellent combination partner used in standard of care," Biomea Chief Executive Thomas Butler said in a statement.

The company's shares were up 3.6% in after-hours activity.

Price: 6.00, Change: +0.21, Percent Change: +3.63

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490081217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490081217","market":"nz","top_or_hot":-1,"title":"Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours","media":"MT Newswires Live","content":"<html><body><p> Biomea Fusion (BMEA) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a \"transformative\" therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer.</p><p>The investigational therapy demonstrated a \"favorable\" safety and tolerability profile in the trial, with no dose-limiting toxicities observed across all dose levels, the company said.</p><p>\"Given the safety profile demonstrated to date, and the lack of myelosuppression, we think BMF-500 could be an excellent combination partner used in standard of care,\" Biomea Chief Executive Thomas Butler said in a statement.</p><p>The company's shares were up 3.6% in after-hours activity.</p><p>Price: 6.00, Change: +0.21, Percent Change: +3.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 06:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biomea Fusion (BMEA) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a \"transformative\" therapy for patients with FMS-like tyrosine kinase 3 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490081217","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490081217","pubTimestamp":1733784236,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biomea Fusion  said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a \"transformative\" therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer.The investigational therapy demonstrated a \"favorable\" safety and tolerability profile in the trial, with no dose-limiting toxicities observed across all dose levels, the company said.\"Given the safety profile demonstrated to date, and the lack of myelosuppression, we think BMF-500 could be an excellent combination partner used in standard of care,\" Biomea Chief Executive Thomas Butler said in a statement.The company's shares were up 3.6% in after-hours activity.Price: 6.00, Change: +0.21, Percent Change: +3.63","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4539":"次新股","BMEA":"Biomea Fusion, Inc.","BK4139":"生物科技"},"translate_title":"Biomea Fusion报告了实验性癌症治疗研究的初步数据；盘后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":1},"content_text":"Biomea Fusion (BMEA) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a \"transformative\" therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer.The investigational therapy demonstrated a \"favorable\" safety and tolerability profile in the trial, with no dose-limiting toxicities observed across all dose levels, the company said.\"Given the safety profile demonstrated to date, and the lack of myelosuppression, we think BMF-500 could be an excellent combination partner used in standard of care,\" Biomea Chief Executive Thomas Butler said in a statement.The company's shares were up 3.6% in after-hours activity.Price: 6.00, Change: +0.21, Percent Change: +3.63","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490081217"}